Tubulin, Beta, 3 (TUBB3) Antikörper

Antigen: Tubulin, Beta, 3 (TUBB3)

Synonyme: TUBB3, TUBB4, MGC134115, MC1R, beta-4, tbb3, M(beta)3, M(beta)6, 3200002H15Rik, tubb3, MGC76202, TUBB1, tubB3, tubulin

Klonalität: Monoklonal (Tuj-1-TubIII-4G3)

Wirt: Maus

Reaktivität: Human

Applikation: Immunzytochemie (ICC), Immunpräzipitation (IP), Western Blot (WB)

Produktnummer: ABIN346893

Produktbeschreibung

Weitere Bezeichnung: Human class III beta-Tubulin

Immunogen: CIII beta-Tubulin protein (Cter domain)

Format: Ascites

Isotyp: IgG1 kappa  (Passende Sekundärantikörper)

Klon: Tuj-1-TubIII-4G3

Spezifität: Monoclonal antibody reacts specifically with human class III beta-Tubulin (55 kDa). Cross Reactivities: Not yet tested

Anwendungen

Applikationshinweise: Optimal dilutions should be determined by the end user. The following are guidelines only: Immunocytochemistry : 1/100 to 1/500. Immunoprecipitation : 1/50 to 1/200. Western Blot : 1/200 to 1/1 000

Buffer: Lyophilized from 200 µl of ascitic fluid. Preservative: None.

Lagerung: Short term storage: +4°C. Long term storage: -20°C

Beschränkungen: Nur für Forschungszwecke einsetzbar

Publikationen

Publikationen: Sueve, Reiman, Lai et al.: "Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site." in: Cancer chemotherapy and pharmacology, Vol. 60, Issue 1, pp. 27-34, 2007 (PubMed).

Sueve, Dumontet: "Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?" in: The lancet oncology, Vol. 9, Issue 2, pp. 168-75, 2008 (PubMed).

Vilmar, Santoni-Rugiu, Sørensen: "Class III {beta}-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial." in: Clinical cancer research : an official journal of the American Association for Cancer Research, 2011 (PubMed). (1:400, Probematerial (Species): Human). Weitere Details: incubating for 20 min with the antibody (Clone TUJ- 14 1/TubIII/4G3) (diluted 1:400) against human TUBB3

Vilmar, Garcia-Foncillas, Huarriz et al.: "RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC." in: Lung cancer (Amsterdam, Netherlands), 2011 (PubMed). (1:400).